Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Serum Bactericidal Assay

Research Leaders

9 sponsors active, led by Alira Health

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 6 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting2
Not Yet Recruiting2
Active Not Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07761026Recruiting

AXIS MG Patient Registry

NCT07033559Not Yet RecruitingPrimary

Detecting Fatigue From Voice in Generalised Myasthenia Gravis

NCT07337395Not Yet RecruitingPrimary

Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab

NCT06906692Active Not RecruitingPrimary

Meningococcal Vaccination in Patients on Complement Inhibitors

NCT06617741Recruiting

Myasthenia Gravis Foundation of America Global MG Patient Registry

NCT00408213Phase 3CompletedPrimary

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Showing all 6 trials

Research Network

Common Treatments

  • Serum Bactericidal Assay1
  • Mycophenolate Mofetil Cellcept1

Active Sponsors

  • Alira Health2
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS2
  • Autoimmune Neurology Alliance1
  • Alexion Pharmaceuticals, Inc.1
  • Myasthenia Gravis Foundation of America1

Top Investigators

Related Conditions

  • Myasthenia Gravis2
  • Myasthenia Gravis Crisis2
  • Myasthenia Gravis Thymectomy2
  • Myasthenia Gravis Exacerbations2
  • Myasthenia Gravis Musk2

Activity Timeline